Navigation Links
ASH and EHA Jointly Announce Translational Research Training in Hematology Program
Date:6/5/2009

BERLIN, June 5 /PRNewswire-USNewswire/ -- In an effort to foster global biomedical research that will ultimately lead to new and improved treatments for patients with blood diseases, the American Society of Hematology (ASH) and the European Hematology Association (EHA) have collaborated to create the Translational Research Training in Hematology (TRTH) program. This program will provide promising translational investigators an opportunity to undertake intensive training in the causes, diagnosis, and experimental treatment of hematologic disorders from some of the most recognized names in the field.

"The next generation of translational researchers will need to understand how to direct research in both the European and U.S. systems," said TRTH co-director and past ASH president Kenneth Kaushansky, MD. "This unique cross-cultural program provides participants with ongoing mentoring, a supportive peer network, and a depth of knowledge and experience that will help position them as global leaders in the field of translational research."

The inaugural TRTH will bring 20 early-career scientists to Marbella, Spain, during the week of March 20-26, 2010. Practical sessions will focus on career development, featuring career retrospectives from leaders in the field of hematology and panel discussions on grant preparation and funding sources; while instructional sessions will prepare participants to conduct hypothesis-driven research, design phase I and II clinical trials, and utilize animal models, diagnostics, and biomarkers in translational research.

"This rigorous one-week training course will allow participants to work with faculty in small groups to review and refine their individual research proposals," said program co-director and EHA president Willem Fibbe, MD. "The goal is for each of them to leave here with a competitive proposal so that they are ready to take the next step in applying for funding. We look fo
'/>"/>

SOURCE American Society of Hematology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. ASH and EHA jointly announce translational research training in hematology program
2. Sisters of Charity Health System & University Hospitals Announce New Agreement for Jointly Owned Hospitals
3. U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia
4. Nucletron and Advanced Radiation Therapy (ART) Jointly Announce a Global, Strategic Partnership to Offer AccuBoost(R) for Image-Guided Breast Irradiation
5. U.S. Preventive Medicine(R), The Mount Sinai Medical Center Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services
6. XIRING and SCM Microsystems Jointly Develop Mobile Terminals for German eHealth Market
7. 3rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide, Inc.
8. Samplify Systems Announces Availability of Compression for Computed Tomography; Integrated Slip-Ring Solution to be Jointly Developed with Schleifring und Apparatebau and Tokyo Electron Device Ltd.
9. PDX-NHIN and Health Market Science to Jointly Market Standardized Prescriber File
10. iPod Repair Site Eases Scam Worries with Unexpected Announcements
11. Ortho Biotech Oncology Research & Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 1Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 2Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting 55979 3Jiangbo Pharmaceuticals to Present at Rodman 26 Renshaw Annual Global Investment Conference 13788 1Jiangbo Pharmaceuticals to Present at Rodman 26 Renshaw Annual Global Investment Conference 13788 2Jiangbo Pharmaceuticals to Present at Rodman 26 Renshaw Annual Global Investment Conference 13788 3September 2009 is Atrial Fibrillation Month 55975 1September 2009 is Atrial Fibrillation Month 55975 2